News

Cosmos Health Inc., a global healthcare conglomerate, reported double-digit revenue growth for Q2 2025, reaching $14.75 million, an 11.66%...

NRx Pharmaceuticals Doubles Down on Ketamine for Suicidal Depression, Secures Strategic Investment NRx Pharmaceuticals is aggressively pursuing a dual-pronged...

Pelthos Therapeutics (NYSE American: PTHS) has officially launched Zelsuvmi™ (berdazimer) topical gel 10.3%, the first FDA-approved at-home treatment for...

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT and LIXTW), a clinical-stage pharmaceutical company developing cancer therapies, has undergone a period...

Annexon Biosciences has announced significant progress across its pipeline of classical complement-mediated neuroinflammatory disease therapies, including positive regulatory momentum...

INVO Fertility Returns to Core Business, But Challenges Remain INVO Fertility reported second-quarter 2025 financial results, marking a return...

Cosciens Biopharma is streamlining its operations and sharpening its focus by voluntarily delisting from the Nasdaq stock market, while...

Inhibikase Therapeutics is advancing IKT-001, a prodrug of imatinib mesylate, towards a Phase 2b clinical trial for pulmonary arterial...

Eledon Pharmaceuticals’ recent Q2 2025 update highlights the emerging potential of its anti-CD40L antibody, tegoprubart, in the complex landscape...

Fortress Biotech’s recent Q2 2025 financial results reveal a company at a pivotal juncture, transitioning from a predominantly development-focused...